All In Biotech

Investigational drug · Phase 3

KRT-232

Also called: Navtemadlin

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 25, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

4 still active

All registered trials

19

Any phase or sponsor naming "KRT-232"

First trial start

2019

Jan 15, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "KRT-232", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Diffuse Large B Cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Lymphoma
  • Endometrial Cancer
  • Polycythemia Vera
  • Myelofibrosis
  • Post-PV MF
  • Post-ET Myelofibrosis
  • Primary Myelofibrosis
  • MF

Approved drugs for the same conditions: Endometrial cancer · Chronic lymphocytic leukemia · Hodgkin lymphoma · Myelofibrosis · Oncology · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "KRT-232" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 32 on PubMed

Also in development for Diffuse Large B Cell Lymphoma

  • BirelentinibDZD8586Phase 37 trials

    Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)

  • TQB2825Phase 33 trials

    Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Diffuse Large Cell B-lymphoma

  • CLR 131I-131-CLR1404, Iopofosine I 131 single dosePhase 32 trials

    Cellectar Biosciences, Inc. · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia

  • TulmimetostatDZR123, Tulmimetostat DL1Phase 23 trials

    Novartis · Progressive Metastatic Castrate Resistant Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Advanced Solid Tumor

  • and prednisonePhase 22 trials

    Genmab · Follicular Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma

  • IMT-009Phase 21 trial

    Immunitas Therapeutics · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.